Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

SC=Subcutaneous

Key Inclusion Criteria:

- Subjects ≥18 years of age

- Diagnosis of Rheumatoid Arthritis confirmed by participant's physician

- Disease activity under control

Key Exclusion Criteria:

- Change in disease-modifying antirheumatic drug (DMARD) therapy within 3 months of
enrollment

- Exposure to investigational drug within 4 weeks or 5 half lives whichever is longer

- Current or prior use of Rituximab ≤6 months

- Current or prior use of the following within 4 weeks or 5 half lives whichever is
longer: biologic DMARDS, Tofacitinib, Cyclophosphamide, Mycophenolate Mofetil &
d-Penicillamine